PPCB Earnings Propanc Biopharma, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–21 of 21
| Q4 2026 (derived) | 2026-06-30 | -16.65 | 2026-09-25 | 10-K |
| FY 2026 | 2026-06-30 | -17.62 | 2026-09-25 | 10-K |
| Q3 2026 | 2026-03-31 | -0.28 | 2026-05-14 | 10-Q |
| Q2 2026 | 2025-12-31 | -0.30 | 2026-02-17 | 10-Q |
| Q1 2026 | 2025-09-30 | -0.39 | 2025-11-14 | 10-Q |
| Q4 2025 (derived) | 2025-06-30 | -290.52 | 2025-09-29 | 10-K |
| FY 2025 | 2025-06-30 | -371.22 | 2025-09-29 | 10-K |
| Q3 2025 | 2025-03-31 | -12.50 | 2025-05-15 | 10-Q |
| Q2 2025 | 2024-12-31 | -32.23 | 2025-02-14 | 10-Q |
| Q1 2025 | 2024-09-30 | -35.97 | 2024-11-14 | 10-Q |
| Q4 2024 (derived) | 2024-06-30 | -33407.87 | 2024-09-30 | 10-K |
| FY 2024 | 2024-06-30 | -35513.25 | 2024-09-30 | 10-K |
| Q3 2024 | 2024-03-31 | -545.79 | 2024-05-15 | 10-Q |
| Q2 2024 | 2023-12-31 | -1559.55 | 2024-02-20 | 10-Q |
| Q1 2024 | 2023-09-30 | -0.04 | 2023-11-14 | 10-Q |
| Q4 2023 (derived) | 2023-06-30 | 1.28 | 2023-09-28 | 10-K |
| FY 2023 | 2023-06-30 | -1.80 | 2023-09-28 | 10-K |
| Q3 2023 | 2023-03-31 | -0.42 | — | — |
| Q2 2023 | 2022-12-31 | -0.53 | — | — |
| Q1 2023 | 2022-09-30 | -2.13 | — | — |
| FY 2022 | 2022-06-30 | -49.23 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.